A new TB vaccine for adolescents and adults, developed by IIT and ILS Bhubaneswar, is set for commercialisation.

Tuberculosis (TB) remains one of the world’s deadliest infectious diseases, claiming 1.23 million lives in 2024 alone, as reported by the WHO. Ending the TB epidemic by 2030 is a key global health ...

The vaccine triggers strong immune responses against Mycobacterium tuberculosis and is licensed for commercial development to ...

Bhubaneswar: The Bhubaneswar-based Indian Institute of Technology (IIT), the Institute of Life Sciences (ILS) along with the ...

Cases of tuberculosis are rising in the UK and US, and experts are urging that a holistic approach to treatment is the best ...

Scientists have uncovered why tuberculosis bacteria evade antibiotics by entering a dormant state. Researchers found that ...

India is moving closer to commercialising a new tuberculosis vaccine — the HSP Subunit Vaccine in Adjuvant (DDA). Developed ...

Bhubaneswar and Institute of Life Sciences (ILS) along with National Research Development Corporation (NRDC) on Monday signed a quadripartite licence agreement (QLA) with TechInvention Lifecare Limit ...

This CDC illustration shows what the tuberculosis bacteria looks like. A Broward high school and Miami’s federal detention center have each confirmed an active case of tuberculosis, one of the ...

The Johns Hopkins Center for Immunization Research is recruiting for a tuberculosis prevention study involving the investigational BCG vaccine ...